Literature DB >> 15617919

Laser in situ keratomileusis for treated anisometropic amblyopia in awake, autofixating pediatric and adolescent patients.

Christopher B Phillips1, Thomas C Prager, Glynett McClellan, Helen A Mintz-Hittner.   

Abstract

PURPOSE: To establish the safety and efficacy of laser in situ keratomileusis (LASIK) in pediatric and adolescent patients with anisometropic amblyopia who completed amblyopia therapy and had a visual acuity of 20/30 or better bilaterally.
SETTING: Department of Ophthalmology and Visual Science, University of Texas-Houston Medical School, Houston, Texas, USA.
METHODS: From August 2000 to March 2002, LASIK was performed in 21 eyes of 19 consecutive patients meeting eligibility requirements. The procedure was performed with the Summit Autonomous LADARVision 4000 excimer laser (Alcon Laboratories, Inc.) in the amblyopic eye for the correction of anisometropia or in both eyes. All patients were awake and autofixating during the procedure.
RESULTS: The mean patient age was 13.14 years (range 8 to 19 years). Seventeen patients were treated in the amblyopic eye only to correct anisometropia; treatment was performed in both eyes of 2 patients who were older than 18 years. Patients were followed for a mean of 18.0 months (range 8.6 to 26.5 months). Anisometropia was greater than 2.00 diopters (D) in all cases (mean 4.43 D, range 13.25 to 2.25 D). The percentage deviation from the attempted correction in the myopic group was 4.0% +/- 4.0% (SD) (range 2.0% to 10.0%) and 38.0% +/- 13.0% (range 5.0% to 58.0%) in the hyperopic group. Anisometropia decreased uniformly to less than 2.00 D in all patients (mean 1.52 D). The percentage of patients with stereo acuity increased from 63.0% preoperatively to 84.0% postoperatively.
CONCLUSIONS: Laser in situ keratomileusis safely and effectively reduced anisometropia in these patients. If stereo acuity is not possible preoperatively, it may be obtained postoperatively.

Entities:  

Mesh:

Year:  2004        PMID: 15617919     DOI: 10.1016/j.jcrs.2004.02.020

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  8 in total

1.  Pediatric Refractive Surgery: A 2015 Perspective.

Authors:  Erin Durrie Stahl
Journal:  Mo Med       Date:  2015 May-Jun

2.  Refractive Surgery for Special-Needs Children with High Myopia.

Authors:  Lawrence Tychsen
Journal:  Mo Med       Date:  2022 Jan-Feb

Review 3.  Myopia: Mechanisms and Strategies to Slow Down Its Progression.

Authors:  Andrea Russo; Alessandro Boldini; Davide Romano; Giuseppina Mazza; Stefano Bignotti; Francesco Morescalchi; Francesco Semeraro
Journal:  J Ophthalmol       Date:  2022-06-14       Impact factor: 1.974

Review 4.  Myopia onset and progression: can it be prevented?

Authors:  Andrea Russo; Francesco Semeraro; Mario R Romano; Rodolfo Mastropasqua; Roberto Dell'Omo; Ciro Costagliola
Journal:  Int Ophthalmol       Date:  2013-09-17       Impact factor: 2.031

5.  Laser in situ keratomileusis for treated myopic anisometropic amblyopia in children.

Authors:  Assad A Ghanem; Ashraf I Moad; Ehab H Nematallah; Ibrahim T El-Adawy; Ghada M Anwar
Journal:  Saudi J Ophthalmol       Date:  2010-01-12

6.  Stereoacuity after photorefractive keratectomy in myopia.

Authors:  Siamak Zarei-Ghanavati; Hamid Gharaee; Alireza Eslampour; Asieh Ehsaei; Mojtaba Abrishami
Journal:  J Curr Ophthalmol       Date:  2016-03-08

7.  Enhanced Gray Matter Volume Compensates for Decreased Brain Activity in the Ocular Motor Area in Children with Anisometropic Amblyopia.

Authors:  Weizhao Lu; Xueliang Yu; Lisheng Zhao; Yanli Zhang; Feng Zhao; Yi Wang; Jianfeng Qiu
Journal:  Neural Plast       Date:  2020-04-16       Impact factor: 3.599

8.  Detection of Static and Dynamic Stereopsis after Femtosecond Laser Small Incision Lenticule Extraction for High Myopia.

Authors:  Aiqun Xiang; Chu Hang; Xiaoying Wu; Yewei Yin; Yanyan Fu; Ying Lu; Kaixuan Du; Tu Hu; Li Yan; Dan Wen
Journal:  J Ophthalmol       Date:  2021-06-11       Impact factor: 1.909

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.